{"id":"single-immediate-chemotherapy-instillation","safety":{"commonSideEffects":["Bladder irritation","Dysuria","Urinary frequency","Hematuria","Chemical cystitis"],"contraindications":["Bladder perforation","Extensive bladder trauma during resection","Known hypersensitivity to the chemotherapy agent used"]},"_chembl":{"chemblId":"CHEMBL2074774","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"The immediate postoperative instillation works by exposing the bladder mucosa to chemotherapeutic agents when it is most vulnerable, typically within 24 hours of tumor resection. This timing prevents floating tumor cells from reimplanting and eliminates microscopic residual disease before wound healing occurs.","oneSentence":"Delivers cytotoxic chemotherapy directly to the bladder lining immediately post-surgery to destroy residual cancer cells and prevent reimplantation."},"_scrapedAt":"2026-03-28T01:34:43.264Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122762,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"mitomycin C","brand":null,"company":null,"rationale":"Commonly used agent for immediate intravesical instillation"},{"name":"epirubicin","brand":null,"company":null,"rationale":"Alternative chemotherapy agent for immediate bladder instillation"},{"name":"BCG immunotherapy","brand":null,"company":null,"rationale":"Alternative intravesical therapy for bladder cancer prevention"}],"description":"Single immediate chemotherapy instillation refers to the administration of chemotherapy directly into the bladder immediately after transurethral resection of bladder tumors. This approach aims to prevent tumor recurrence by eliminating residual cancer cells and preventing tumor cell reimplantation.","indications":{"approved":[{"status":"investigational","condition":"Non-muscle invasive bladder cancer","patientPopulation":"Adult patients following transurethral resection of bladder tumor (TURBT)"}]},"trialDetails":[{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT05975151","phase":"PHASE2","title":"Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":"Bladder Cancer","enrollment":63},{"nctId":"NCT01675219","phase":"PHASE3","title":"Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2012-12","conditions":"Bladder Cancer","enrollment":400},{"nctId":"NCT02438865","phase":"PHASE2","title":"Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2015-01-01","conditions":"Neoplasm, Ureter, Neoplasm, Bladder","enrollment":74},{"nctId":"NCT02214602","phase":"PHASE4","title":"Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2014-07","conditions":"Carcinoma of Urinary Bladder, Superficial","enrollment":240},{"nctId":"NCT02740426","phase":"PHASE2","title":"Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2016-08","conditions":"Upper Tract Urothelial Carcinoma, Bladder Recurrence","enrollment":200},{"nctId":"NCT02923557","phase":"PHASE2","title":"Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2016-11","conditions":"Bladder Recurrence, Upper Tract Urothelial Carcinoma, Nephroureterectomy","enrollment":200},{"nctId":"NCT00003725","phase":"PHASE3","title":"Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer","status":"UNKNOWN","sponsor":"Anthra Pharmaceuticals","startDate":"1996-12","conditions":"Bladder Cancer","enrollment":300},{"nctId":"NCT00042887","phase":"PHASE3","title":"Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer","status":"TERMINATED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-05","conditions":"Bladder Cancer","enrollment":58},{"nctId":"NCT01149174","phase":"PHASE3","title":"Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"1994-01","conditions":"Superficial Bladder Cancer","enrollment":352}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["single instillation"],"phase":"phase_3","status":"active","brandName":"single immediate chemotherapy instillation","genericName":"single immediate chemotherapy instillation","companyName":"Turku University Hospital","companyId":"turku-university-hospital","firstApprovalDate":"","aiSummary":"Toripalimab is being studied as a treatment for urinary bladder neoplasms, including non-muscle-invasive bladder cancer, in clinical trials. Intravesical instillation of Gemcitabine and Mitomycin C is also being investigated as a treatment for these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}